Name | denileukin diftitox |
---|---|
Synonyms | DENILEUKIN DIFTITOX |
Description | Denileukin diftitox (DAB 389IL-2) is a diphtheria toxin (DT)-related interleukin 2 (IL-2) fusion protein toxin that depletes cells expressing the high-affinity form of the IL-2 receptor (IL-2R), CD25. Denileukin diftitox binds to cells expressing IL-2R and inhibits protein synthesis through internalization of the diphtheria toxin fragment[1][2][3]. |
---|---|
Related Catalog | |
Target |
IL-2 receptor (IL-2R), CD25[1] |
In Vitro | Denileukin diftitox (DAB 389IL-2) 是一种 3 结构域融合蛋白毒素,由白喉毒素 (DT) 催化结构域、白喉毒素 (DT) 膜易位结构域和取代天然白喉毒素 (DT) 受体结合结构域的人 IL-2 组成[1]。 Denileukin diftitox (1-1000 pM; HUT 102/6TG 细胞) 对于体外携带高亲和力 IL-2 受体的细胞系细胞毒效力增加了大约 17 倍[3]。 |
In Vivo | Denileukin diftitox (DAB 389IL-2; 35 μg/kg; i.p.; 感染 H37Rv 的 C57BL/6 小鼠) 在小鼠模型中抑制分枝杆菌复制并降低 Treg 和髓源性抑制细胞 (MDSC) 的频率[1]。 Denileukin diftitox (2.5 或 3 μg/头; i.v.) 在小鼠模型中具有抗肿瘤活性并抑制肿瘤生长[2]。 Animal Model: C57BL/6 mice with infected H37Rv[1] Dosage: 35 μg/kg Administration: Intraperitoneal injection; twice a week, for 2 weeks Result: Reduced the colony-forming unit (CFU) numbers in lungs and spleens. Reduces Treg and MDSC frequencies in lungs and spleens. Animal Model: Female BALB/c mice with tumor models[2] Dosage: 2.5 or 3 μg/head Administration: Intravenous injection; weekly, for 2 or 3 weeks Result: Inhibited the growth of tumors. |
References |
No Any Chemical & Physical Properties |